SCM
CHRS icon

Sterling Capital Management’s Coherus Oncology CHRS Stock Holding History

Sterling Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Sell
1,865
-730
-28% -$1.19K ﹤0.01% 2915
2026
Q1 		$4.39K Sell
2,595
-1,758
-40% -$3.12K ﹤0.01% 2785
2025
Q4 		$6.18K Sell
4,353
-672
-13% -$979 ﹤0.01% 2818
2025
Q3 		$8.24K Buy
5,025
+2,731
+119% +$3.04K ﹤0.01% 2593
2025
Q2 		$1.68K Buy
2,294
+787
+52% +$679 ﹤0.01% 2960
2025
Q1 		$1.22K Sell
1,507
-1,316
-47% -$1.51K ﹤0.01% 2751
2024
Q4 		$3.9K Buy
2,823
+2,535
+880% +$2.84K ﹤0.01% 2566
2024
Q3 		$300 Buy
+288
New +$395 ﹤0.01% 3033

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Sterling Capital Management's CHRS Position: Q2 2026 in Review

Sterling Capital Management reduced its Coherus Oncology (CHRS) stake by 28% in Q2 2026, selling an estimated $1.19K and leaving 1,865 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2915.

Sterling Capital Management first reported a position in CHRS in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.24K in Q3 2025. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Sterling Capital Management held 1,865 shares of Coherus Oncology worth $2.61K as of Q2 2026.
  • Sterling Capital Management sold 730 Coherus Oncology shares in Q2 2026, an estimated $1.19K.
  • Coherus Oncology made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2915 holding.
  • Sterling Capital Management first reported a position in Coherus Oncology in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Coherus Oncology position peaked at $8.24K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.